OSI Pharmaceuticals, Inc. announced today that its UK subsidiary focused on the discovery and development of diabetes and obesity therapeutics has granted a worldwide non-exclusive license under its DPIV patent portfolio to a major British pharmaceutical company. The portfolio covers the use of DPIV inhibitors for the treatment of type 2 diabetes and related indications. OSI will receive upfront, milestone and royalty payments. Additional financial terms were not disclosed.
Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1131855XSL_NEWSML_TO_NEWSML_WEB.xml)